Differences in the Endocannabinoid System of Sperm from Fertile and Infertile Men

Abstract

Male infertility is a major cause of problems for many couples in conceiving a child. Recently, lifestyle pastimes such as alcohol, tobacco and marijuana have been shown to have further negative effects on male reproduction. The endocannabinoid system (ECS), mainly through the action of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) at cannabinoid (CB1, CB2) and vanilloid (TRPV1) receptors, plays a crucial role in controlling functionality of sperm, with a clear impact on male reproductive potential. Here, sperm from fertile and infertile men were used to investigate content (through LC-ESI-MS), mRNA (through quantitative RT-PCR), protein (through Western Blotting and ELISA) expression, and functionality (through activity and binding assays) of the main metabolic enzymes of AEA and 2-AG (NAPE-PLD and FAAH, for AEA; DAGL and MAGL for 2-AG), as well as of their binding receptors CB1, CB2 and TRPV1. Our findings show a marked reduction of AEA and 2-AG content in infertile seminal plasma, paralleled by increased degradation: biosynthesis ratios of both substances in sperm from infertile versus fertile men. In addition, TRPV1 binding was detected in fertile sperm but was undetectable in infertile sperm, whereas that of CB1 and CB2 receptors was not statistically different in the two groups. In conclusion, this study identified unprecedented alterations of the ECS in infertile sperm, that might impact on capacitation and acrosome reaction, and hence fertilization outcomes. These alterations might also point to new biomarkers to determine male reproductive defects, and identify distinct ECS elements as novel targets for therapeutic exploitation of ECS-oriented drugs to treat male fertility problems.

About the Authors:

Sheena E. M. Lewis

Contributed equally to this work with: Sheena E. M. Lewis, Cinzia Rapino

Affiliation: School of Medicine, Centre for Public Health, Queen’s University Belfast, Institute of Clinical Science, Belfast, United Kingdom

Cinzia Rapino

Contributed equally to this work with: Sheena E. M. Lewis, Cinzia Rapino

Affiliation: Department of Biomedical Sciences, University of Teramo, Teramo, Italy

Monia Di Tommaso

Affiliation: Department of Biomedical Sciences, University of Teramo, Teramo, Italy

Mariangela Pucci

Affiliation: Department of Biomedical Sciences, University of Teramo, Teramo, Italy

Natalia Battista

Affiliation: Department of Biomedical Sciences, University of Teramo, Teramo, Italy

Rita Paro

Affiliation: School of Medicine, Centre for Public Health, Queen’s University Belfast, Institute of Clinical Science, Belfast, United Kingdom

Luke Simon

Affiliation: School of Medicine, Centre for Public Health, Queen’s University Belfast, Institute of Clinical Science, Belfast, United Kingdom

Deborah Lutton

Affiliation: Regional Fertility Centre, Royal Jubilee Maternity Services, Belfast, United Kingdom

Mauro Maccarrone

* E-mail: [email protected]

Affiliations Department of Biomedical Sciences, University of Teramo, Teramo, Italy, European Center for Brain Research (CERC)/IRCCS Santa Lucia Foundation, Rome, Italy

Introduction

One in six couples has difficulty in conceiving, with the male factor being the primary cause of infertility in 40% of couples. This may depend on a reduced number of sperm due to impaired spermatogenesis or abnormal maturation, or it may be caused by sperm dysfunction from metabolic deregulation or oxidative stress. Recently, lifestyle pastimes such as alcohol, tobacco and marijuana have been shown to have further negative effects on male reproduction [1]–[3].

Conventional semen analysis continues to be the only routine test to diagnose male infertility; however, it cannot discriminate between sperm of fertile and infertile men [4]. For a test to be useful diagnostically or prognostically, it must have little overlap between groups of fertile and infertile men. Routine semen analysis does not meet these standards [4]–[7]. Hence, more sensitive biomarkers of male infertility are urgently needed.

Recent studies [8]–[10] have shown that the endocannabinoid system is a key player in the multifaceted process of male reproduction. In this study we characterised, for the first time, all major components of the ECS in sperm of fertile and infertile men.

Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound extracted from Cannabis sativa, impairs spermatogenesis and sperm function, and acts to reduce the release of testosterone [11]–[13]. Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the best characterized endocannabinoids (eCBs). Both are endowed with distinct biological activities in the central nervous system (CNS) and in the periphery, where they mimic several actions of THC [14]–[15]. eCBs act principally through cannabinoid receptors, which are members of the rhodopsin family of G protein-coupled seven-transmembrane spanning receptors [16], and include type-1 and type-2 cannabinoid (CB1 and CB2) receptors as the best characterized targets of eCBs. CB1 has been found mainly in the central nervous system [17], but is present also in ovary [18], testis [19], vas deferens [20], and other peripheral endocrine and neurological tissues [21]–[22]. CB2 has been found mainly in peripheral and immune cells [23], but also in neuronal cells [24]–[25] and reproductive cells and tissues [26]. Recently, other CB receptors, like the purported “CB3” receptor (GPR55) [27]–[28], and non-CB1/non-CB2 receptors have been identified. Among the latter, non-selective cationic channel type-1 vanilloid receptor (transient receptor potential vanilloid 1, TRPV1), activated by capsaicin and by noxious stimuli like heat and protons, is an additional target of AEA, but not of 2-AG [29]. eCBs are released from membrane phospholipid precursors through the activation of specific phospholipases [30], that are activated “on demand”. Although AEA synthesis may occur via multiple biosynthetic pathways [31], the most prominent route is catalysed by an N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) [32]. Similarly, the formation of 2-AG involves a rapid hydrolysis of inositol phospholipids by a specific phospholipase C (PLC) to generate diacylglycerol (DAG), which is then converted into 2-AG by an sn-1-DAG lipase (DAGL) [33]. After re-uptake through a purported specific transporter [34] and intracellular trafficking to selected targets [35]–[36], eCBs signalling is terminated by hydrolysis via fatty acid amide hydrolase (FAAH) [37] for AEA, and via a specific monoacylglycerol lipase (MAGL) for 2-AG [38]. Taken together eCBs, their molecular targets (CB1, CB2, TRPV1), and their metabolic enzymes form the so-called endocannabinoid system (ECS). Distinct ECS elements have been identified in seminal plasma [39], male reproductive tissues [40], Leydig and Sertoli cells [19], [41]–[42], as well as in male germ cells [41]–[47], from spermatogonia to mature spermatozoa [44], [48]–[50]. Overall, the present evidence supports an “evolutionary” role of ECS (and in particular of CB1 and FAAH) as check points in reproduction [3], [9]–[10], [51]–[53].

The presence of N-acylethanolamines (NAEs), such as AEA, N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA), in human seminal plasma [39] further suggests that eCB signalling takes part in regulating capacitation and fertilizing potential within human reproductive tracts. Indeed, evidence for the existence of an active eCBs signalling in sperm has been demonstrated in sea urchin and also in humans [54]–[57]. AEA, through the activation of CB1, decreases the motility of human sperm and reduces their capacitation ability [58]. In addition, by activating TRPV1, AEA reduces the fusion of the human sperm membrane with that of the oocyte [48]. However, at present, there are no data on possible alterations of ECS elements in sperm from fertile versus infertile men.

The aim of the present study was to investigate the expression and functional activity of the main ECS elements in sperm obtained from fertile and infertile men, in order to ascertain whether alterations in eCBs metabolism and/or receptor activity could be associated with male infertility.

Materials and Methods

Reagents

Chemicals were of the purest analytical grade. Anandamide (N-arachidonoylethanolamine, AEA) and 5-(1,10-dimethylheptyl)-2-[(1R,5R)-hydroxy-(2R)-(3-hydroxypropyl)-cyclohexyl] phenol (CP55940) were purchased from Sigma Chemical Company (St. Louis, MO, USA). N-Arachidonoyl-phosphatidylethanolamine (NArPE) was synthesized from arachidonic acid and phosphatidylethanolamine as reported [59]. [3H]CP55,940 (136.9 Ci/mmol), [3H]AEA (60 Ci/mmol) and [3H]resinferatoxin ([3H]RTX, 43 mCi/mmol) were from PerkinElmer Life Sciences (Boston, MA, USA). [3H]NArPE (200 Ci/mmol), [3H]2-oleoyl-glycerol ([3H]2-OG, 20 Ci/mmol) and [3H]2-arachidonoylglycerol ([3H]2-AG, 200 Ci/mmol) were from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). [14C]Diacylglycerol ([14C]DAG, 56 mCi/mmol) was from Amersham Biosciences. RTX and 2-AG were purchased from Alexis Corporation (San Diego, CA). Deuterated AEA (d8-AEA) and 2-AG (d8-2-AG) were from Sigma Chemical Company and Cayman Chemicals (Ann Arbor, MI, USA), respectively. Rabbit anti-CB1 and anti-MAGL polyclonal antibodies were from Cayman Chemicals; rabbit anti-CB2 polyclonal antibody was from Affinity BioReagents (Golden, CO, USA); rabbit anti-NAPE-PLD polyclonal antibody was from Novus Biologicals (Littleton, CO, USA); rabbit anti-FAAH, anti-TRPV1 and anti-β-actin polyclonal antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit anti-DAGL polyclonal antibody was from Frontier Science Co. Ltd. (Okkaido, Japan), and horseradish peroxidise (HRP)-conjugated secondary antibody and non-fat dry milk were from Biorad (Hercules, CA, USA). Bovine serum albumin was from Sigma Chemical Company. West Dura Chemiluminescence System and 3,3′,5,5′-tetramethylbenzidine (TMB) were from Pierce (Rockford, IL, USA).

Semen of Fertile and Infertile Men

This project was approved by the Office for Research Ethics Committees in Northern Ireland and the Royal Group of Hospitals Trust Clinical Governance Committee. The study was conducted at the Regional Fertility Centre, Royal Jubilee Maternity Services, Belfast, Northern Ireland (UK) during the period September, 2005 to December, 2010. Sperm samples for research were obtained after written consent was given by each couple.

Semen from 30 fertile men was obtained from Cryos International, Aarhus (Denmark) and from Androgen Centro Infertilidad Masculina, La Coruna (Spain). Each donor was: a) physically and mentally healthy, b) not suffering from any kind of hereditary disease, c) seronegative for the human immunodeficiency viruses (HIV) 1 and 2, syphilis, viral hepatitis B and C, herpes, cytomegalovirus, d) with no bacterial infection in blood and semen cultures, and e) with a seminal profile exceeding minimal characteristics by WHO guidelines [60].

Semen from 150 infertile men, surplus to clinical requirements, were collected by masturbation after 2–5 days of recommended abstinence.

Following measurement of semen volume, samples were subjected to conventional light microscopic semen analysis within 1 hour of ejaculation, following a period of incubation at 37°C to allow for liquefaction according to WHO recommendations [61], in order to determine sperm concentration and motility. Sperm morphology was assessed according to Kruger Strict Criteria [62]. Following light microscopic analysis, semen was centrifuged at 1500 rpm for 5 minutes. The supernatant was drawn off and the pellet was frozen and stored (−20°C) prior to ECS characterization.

qRT-PCR Analysis

RNA was extracted from sperm using the RNeasy extraction kit (Qiagen, Crawley, UK), as suggested by the manufacturer. Quantitative real time reverse transcriptase-polymerase chain reaction (qRT-PCR) assays were performed using the SuperScript III Platinum Two-Step qRT-PCR Kit (Invitrogen, Carlsbad, CA, USA) as reported [63]. One µg total RNA was used to produce cDNA with 10 U/µL SuperScript III reverse transcriptase, in the presence of 2 U/µL RNaseOUT, 1.25 µM oligo(dT)20, 1.25 ng/µL random hexamers, 5mM MgCl2, 0.5 mM dNTP mix and DEPC-treated water. The reaction was performed using the following qRT-PCR program: 25°C for 10 min, 42°C for 50 min, 85°C for 5 min; then, after addition of 0.1 U/µL of E. coli RNase H, the product was incubated at 37°C for 20 min. The target transcripts were amplified using an ABI PRISM 7700 sequence detector system (Applied Biosystems, Foster City, CA), with the following primers: human CB1 F (5′-CCTTTTGCTGCCTAAATCCAC-3′); human CB1 R (5′-CCACTGCTCAAACATCTGAC-3′); human CB2 F (5′-TCAACCCTGTCATCTATGCTC-3′); human CB2 R (5′-AGTCAGTCCCAACACTCATC-3′); human TRPV1 F (5′-TCACCTACATCCTCCTGCTC-3′); human TRPV1 R (5′-AAGTTCTTCCAGTGTCTGCC-3′); human NAPE-PLD F (5′-TTGTGAATCCGTGGCCAACATGG-3′); human NAPE-PLD R (5′-TACTGCGATGGTGAAGCACG-3′); human FAAH F (5′-CCCAATGGCTTAAAGGACTG-3′); human FAAH R (5′-ATGAACCGCAGACACAAC-3′); human DAGL F (5′-TTCCAAGGAGTTCGTGACTGC-3′); human DAGL R (5′-TTGAAGGCCTTGTTGTCGCC-3′); human MAGL F (5′-ATGCAGAAAGACTACCCTGGGC-3′); human MAGL R (5′-TTATTCCGAGAGAGCACGC-3′); human β-actin F (5′-TGACCCAGATCATGTTTGAG-3′); human β-actin R (5′-TTAATGTCACGCACGATTTCC-3′). β-Actin was used as housekeeping gene for quantification. One µl of the first strand of cDNA product was used (in triplicate) for amplification in 25 µl reaction solution, containing 12.5 µl of Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA) and 10 pmol of each primer. The following PCR program was used: 95°C for 10 min; 40 amplification cycles at 95°C for 30 sec, 56°C for 30 sec, and 72°C for 30 sec [63].

Expression of ECS Elements

Sperm homogenates (50 µg/lane) were subjected to SDS-PAGE on a 10% polyacrylamide gel and electroblotted onto a nitrocellulose membrane as described [63]. Blots were blocked with 10% non-fat dry milk and 5% bovine serum albumin for 2 h, and then incubated with anti-NAPE-PLD (diluted 1∶1000), anti-FAAH (diluted 1∶1000), anti-DAGL (diluted 1∶1000), anti-MAGL (diluted 1∶200), anti-CB1 (diluted 1∶100), anti-CB2 (diluted 1∶300), anti-TRPV1 (diluted 1∶200) and anti-β-actin (diluted 1∶1000) primary antibodies. After washing, filters were incubated with the horseradish peroxidise (HRP)-conjugated secondary antibody (diluted 1∶1000) and the detection was carried out using West Dura Chemiluminescence System [63]. Protein expression levels were quantified by densitometric analysis, using the ImageJ software after normalization with β-actin [64].

Protein expression of ECS elements was also determined by enzyme linked immunosorbent assay (ELISA), as reported [65]. Briefly, wells were coated with sperm homogenates (20 µg/well) and were incubated for 1 h at room temperature with the same antibodies and at the same dilutions used in Western blotting analysis. After rinsing three times with 5% BSA/PBS-Tween 20, 100 µl of HRP-conjugated secondary antibody (diluted 1∶5000) was added and the ELISA plate was further incubated for 30 min at room temperature. The HRP enzymatic activity was determined by the addition of 100 µL/well of tetramethylbenzidine (TMB) containing H2O2 (0.002%), and the absorbance was read on a Multiskan ELISA Microplate Reader (Thermo Labsystems, Bevery, MA, USA) at 450 nm.

AEA Metabolism

The synthesis of [3H]AEA by NAPE-PLD was assayed in sperm extracts (200 µg/test), by using 100 µM [3H]NArPE and reversed phase-high performance liquid chromatography (RP-HPLC), coupled to online scintillation counting [59]. The hydrolysis of 10 µM [3H]AEA by FAAH was assayed in sperm extracts (50 µg/test), by measuring the release of [3H]ethanolamine as reported [59].

2-AG Metabolism

The synthesis of 2-AG by DAGL was evaluated in sperm homogenates (200 µg/test) by measuring the release of [14C]2-AG from [14C]DAG by thin layer chromatography and scintillation counting [50]. The hydrolysis of 2-AG by MAGL was assayed by measuring the release of [3H]glycerol from [3H]2-OG by scintillation counting [50].

Receptor Binding Assays

For cannabinoid receptors studies, membrane fractions from sperm were prepared as reported [44], and were stored at –80°C. Membrane fractions (50 µg/test) were used in rapid-filtration assays [44] with the synthetic cannabinoid [3H]CP55.940 (400 pM), that binds to both CB1 and CB2 receptors [66].The binding of the TRPV1 agonist [3H]RTX (500 pM) was also evaluated by rapid-filtration assays [48]. In all experiments, unspecific binding was determined in the presence of cold agonists (1 µM CP55.940 or 1 µM RTX), as reported [65].

Endogenous Levels of eCBs

Purified sperm and seminal plasma were subjected to lipid extraction with chloroform/methanol (2∶1, v/v), in the presence of d8-AEA and d8-2-AG as internal standards [67]. The organic phase was dried and then analysed by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS), using a single quadrupole API-150X mass spectrometer (Applied Biosystem, CA, USA) coupled with a Perkin Elmer LC system (Perkin Elmer, MA, USA). Quantitative analysis was performed by selected ion recording over the respective sodiated molecular ions [48].

Statistical Analysis

Data were analyzed in the GraphPad Prism statistical PC program using the non-parametric Mann-Whitney U-test (GraphPad Software, San Diego, CA). A level of p<0.05 was considered statistically significant. All data were reported as mean ± S.E.M. of at least three independent experiments, each performed in duplicate.

Results

Demographics of Semen from Fertile and Infertile Men

Semen from fertile donors had sperm concentrations ranging from 48–136 million/mL, morphologies of 5–16% and motilities of 24–62% (Table 1). Semen from infertile patients had concentrations of 2–207 million/mL, morphologies of 2–17% and motilities of 1–66% (Table 1). No significant differences were found between fertile and infertile men. These data show that none of the parameters routinely used for semen analysis is indicative of a man’s fertility potential.

[Figure omitted. See PDF.]

Table 1. Demographic data of fertile and infertile men.

https://doi.org/10.1371/journal.pone.0047704.t001

Expression of ECS Genes and Proteins in Sperm from Fertile and Infertile Men

The results of qRT-PCR experiments on gene expression of the main components of ECS in sperm from fertile and infertile men are shown in Table 2. In terms of AEA metabolism, NAPE-PLD and FAAH genes were expressed to similar extents in both groups. Instead, a significant decrease of DAGL (p<0.01) and MAGL (p<0.05) mRNA levels was found in infertile versus fertile sperm. In addition, the mRNA levels of both CB1 and CB2 receptors were lower in infertile than fertile sperm (p<0.05). Furthermore, a trend towards decreased mRNA levels of TRPV1 was observed in infertile versus fertile sperm (Table 2).

[Figure omitted. See PDF.]

Table 2. Gene expression at mRNA level of ECS elements in human sperm.

https://doi.org/10.1371/journal.pone.0047704.t002

Next, to determine the possible changes of ECS elements at protein level between fertile and infertile sperm, Western blot analysis was performed. Figure 1A shows a representative immunoblot of fertile versus infertile sperm obtained from single donors. Specific anti-NAPE-PLD, anti-FAAH, anti-DAGL, and anti-MAGL antibodies, as well as anti-CB1, anti-CB2 and anti-TRPV1 antibodies recognized a single immunoreactive band of the expected molecular size, both in fertile and infertile sperm. Protein levels of ECS elements, analyzed by densitometry, did not change between the two groups (Fig. 1B), an observation that was corroborated by a more quantitative ELISA analysis (Fig. 1C). Incidentally, the presence of CB1, CB2, TRPV1, NAPE-PLD and FAAH in fertile human sperm extends previous findings [48], whereas the presence of DAGL and MAGL in these cells is unprecedented. On a general note, some discrepancies were observed between the mRNA and protein expression of the ECS elements analyzed. However, it should be recalled that disparities among mRNA abundance and protein levels of proteins are not unprecedented [68], also in the context of the ECS [63]–[64], [69]. It can be speculated that distinct regulatory mechanisms of the steady state levels of mRNAs and proteins might be responsible for the observed differences.

[Figure omitted. See PDF.]

Figure 1. Protein expression of the ECS elements in human sperm.

Representative Western blots (A) and densitometric analysis of the immunoreactive bands (B) of the ECS elements in fertile and infertile sperm. The expected molecular mass of each protein is reported on the right-hand side. C) Protein content of the ECS elements determined by ELISA assay in fertile and infertile sperm, expressed as absorbance units at 450 nm.

https://doi.org/10.1371/journal.pone.0047704.g001

Activity of ECS Elements in Sperm from Fertile and Infertile Men

Table 3 shows the activity of ECS elements tested in sperm from fertile and infertile men. Interestingly, NAPE-PLD and FAAH activities were significantly decreased in sperm from infertile versus fertile men. In particular, in infertile sperm NAPE-PLD and FAAH were reduced respectively compared with ∼25% and ∼50% of the values in fertile sperm. In addition, a trend towards decreased DAGL and MAGL activities was observed in infertile versus fertile sperm. Interestingly, the ratio between FAAH and NAPE-PLD activity (from ∼19 to ∼40) and that between MAGL and DAGL activity (from ∼2.5 to ∼5.0) almost doubled in infertile versus fertile sperm (Table 3). Therefore, infertile sperm seem to improve the overall catabolism of eCBs. Also a slight, yet not statistically significant, decrease of pan-CBR binding was found in sperm from infertile versus fertile men, and a dramatic decrease of TRPV1 binding was detected in infertile versus fertile sperm. Since the mRNA and protein expression of the latter receptor differed little between fertile and infertile sperm, it is proposed that a different intracellular localization might have masked the binding site of TRPV1 in infertile sperm, thus preventing its accessibility by the ligand. Unfortunately, the paucity of sperm samples from donors with proven fertility did not allow further investigation of this hypothesis, nor was further assessment of receptor functionality possible (e.g., in sperm capacitation or calcium mobilization assays). Further studies are needed to elucidate the characteristics of TRPV1 fully.

[Figure omitted. See PDF.]

Table 3. Activity of ECS elements in human sperm.

https://doi.org/10.1371/journal.pone.0047704.t003

Endocannabinoid Levels in Seminal Plasma and Sperm from Fertile and Infertile Men

Consistent with the activity data, a significant reduction in AEA (p<0.0001) and 2-AG (p<0.01) levels was found in seminal plasma of infertile versus fertile men, but not in infertile versus fertile sperm (Table 4). Moreover, a higher content of 2-AG compared with that of AEA was detected in all groups tested, and overall infertile samples presented a lower amount of eCBs with respect to fertile samples (Table 4).

[Figure omitted. See PDF.]

Table 4. Endocannabinoid levels in human sperm.

https://doi.org/10.1371/journal.pone.0047704.t004

Discussion

Previous studies demonstrated the presence of a fully functional AEA-related ECS in sperm obtained from sea urchin [43], frog [70], mouse [50], boar [44], bovine [71], and human [48]. Recently, our group has also provided evidence that the AEA-binding TRPV1 receptor could play a role in the acquisition of sperm fertilizing ability in humans [48].

In order to further our understanding of the role of ECS in male fertility, here we investigated AEA and 2-AG metabolism in sperm from infertile versus fertile men, aiming at ascertaining any difference in the expression and/or activity of ECS elements possibly associated with male infertility. We found a substantial modulation of AEA metabolism in sperm from infertile men. The biosynthesis of AEA through NAPE-PLD and, to a lesser extent, its degradation by FAAH, were both significantly impaired in infertile versus fertile sperm, leading to a significant reduction of AEA content in seminal plasma of infertile sperm. These results are somewhat reminiscent of previous data obtained in maternal lymphocytes, where an association between decreased activity of FAAH and early pregnancy failure was demonstrated [72]; yet, in women who miscarried the AEA content in blood increased [73]. Here, low AEA levels is in keeping with the decreased CB1 and CB2 binding observed in sperm from infertile men. In this context, high intracellular levels of AEA are essential to promote the fertilizing ability of both boar [44], bovine [74] and human sperm [48], by activating TRPV1 receptors at an intracellular binding site. Indeed, TRPV1 ion channels are key players in capacitation and acrosome reaction [75], which are critical steps in sperm fertilizing ability [76]–[78].

Mammalian sperm cannot penetrate the oocyte’s zona pellucida immediately after ejaculation. A final stage of maturation called capacitation must first be completed. Capacitation is the process during which sperm’s motility pattern changes from progressive motility to a very energetic, non-progressive pattern hyperactivated motility where increased flagellar curvature and wider lateral head movements provide the sperm with more strength to penetrate the outer vestments and cumulus cells of the oocyte. This process is facilitated by a calcium influx. Another feature of capacitation that further aids the process of fertilization is the sperm’s ability to undergo the acrosome reaction. The regulation of this capacitated state is closely associated with the sperm’s proximity to the oocyte. If the process is initiated too early, that sperm will be infertile [76]–[78].

In this context, AEA takes part in regulating sperm capacitation, by producing an increase in sperm calcium concentration via TRPV1 channels [71], [74]. The consistent absence of detectable TRPV1 activity in infertile sperm, concomitant with the low levels of AEA detected in seminal plasma of infertile men could lead to a reduced fertilizing capacity of AEA. In addition, as TRPV1 ion channels contribute to the choice between cell survival and death during spermatogenesis in murine sperm [49], a decrease of sperm TRPV1 could be at least partly responsible for the oligospermia of infertile men. In addition, AEA present in both seminal plasma and uterine fluids prevents premature capacitation in freshly ejaculated sperm via a CB1-dependent signalling pathway [10], [53], a defense mechanism that may be impaired in infertile men.

The ECS plays a physiological role in maintaining a quiescent, uncapacitated condition before sperm interacts with the oocyte [47]. Therefore, it may be speculated that the reduction of AEA causes infertile sperm to lose their quiescent state and with that, the ability to prevent premature capacitation. This could then precipitate a premature acrosome reaction rendering that sperm infertile by its inability to penetrate an oocyte in vivo, or indeed in assisted conception such as in in vitro fertilization. This hypothesis is further supported by work from one of our groups [79], where the converse occurred: direct exposure of sperm to recreational concentrations of THC reduced acrosome reactions in vitro.

Using an animal model, we have also shown how the deregulation of the endocannabinoid system markedly impaired spermatogenesis with reductions in total sperm count, depleted spermatogenic efficiency and impaired sperm motility by short and long term exposure to HU210, a selective agonist for CB1 and CB2 receptors [3].

Additionally, the present findings show for the first time that components related to 2-AG metabolism are present in human sperm, extending recent data in murine sperm [50]. Much alike AEA, we report an increased synthesis: degradation ratio of 2-AG in infertile versus fertile sperm, paralleled by a lower concentration of 2-AG in seminal plasma of infertile versus fertile men. Interestingly, a regulatory role of 2-AG has been identified at the start up of mouse epididymal sperm. In particular, along the epididymis, sperm from caput to cauda encounter a decreasing concentration of 2-AG, that induces them to acquire the potential to become motile through CB1 activation [80]. Such a 2-AG gradient is controlled by a tight equilibrium between DAGL and MAGL activity in the epididymal tissues [80]. In addition AEA and 2-AG, by acting extracellularly at CB1 (and AEA also intracellularly at TRPV1), may play a key-role in controlling the spatio-temporal interaction of sperm with oocyte and sperm–oocyte fusion [50]. Therefore, in infertile men a decrease of 2-AG levels in seminal plasma could also reduce the fertilizing capacity of sperm through a mechanism yet to be explored.

Failed fertilization occurs in up to 10% of in vitro fertilization treatment cycles. Since the majority of fertility treatments are self-funded, this is a major expense to infertile couples. The current evaluation of the fertility potential of the male partner, and hence the fertility treatment choice, is based on semen analysis. However, semen parameters have failed to discriminate fertile and sub-fertile men as seen in this study and also reported by Giwercman and colleagues [81]. The present identification of the ECS as a family of new biomarkers to determine male infertility with more accuracy has enormous potential in the fertility clinic.

In conclusion, we report for the first time the presence of ECS components of 2-AG-related metabolism in human sperm and we show an overall reduction of AEA and 2-AG biosynthesis in sperm from infertile versus fertile men. More interestingly, these findings suggest that the functional loss of TRPV1 in infertile sperm could cause a loss of capacitation including the acrosome reaction, thus affecting negatively the interaction between sperm and oocyte, and ultimately resulting in fertilization failure. This is the first characterisation of ECS in human fertile versus infertile sperm, and provides compelling data that identify a previously unknown defect in male fertility. Our results open the opportunity for therapeutic exploitation of ECS-targeted drugs to treat male fertility problems, as well as for exploiting differences in semen ECS constituents to diagnose infertility. The possible involvement of new players of endocannabinoid signalling, such as GPR55, remains to be addressed in an independent investigation.

Acknowledgments

The authors wish to thank Giuseppina Catanzaro and Lucia Borriello (University of Teramo) for their expert assistance with preliminary biochemical analysis. We gratefully acknowledge the contributions of donor sperm from Cryos International (Denmark), ApS, Vesterbro Torv 1-3,5, Aarhus C (Denmark), and Professor Juan Alvarez, Androgen Centro Infertilidad Masculina (La Coruna, Spain).

Author Contributions

Conceived and designed the experiments: MM SEML. Performed the experiments: CR MDT MP NB RP LS DL. Analyzed the data: CR NB. Contributed reagents/materials/analysis tools: MM. Wrote the paper: SEML CR MM.

Citation: Lewis SEM, Rapino C, Di Tommaso M, Pucci M, Battista N, Paro R, et al. (2012) Differences in the Endocannabinoid System of Sperm from Fertile and Infertile Men. PLoS ONE 7(10): e47704. https://doi.org/10.1371/journal.pone.0047704

References

1. Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352(9140): 1611–1616.

2. Sadeu JC, Hughes CL, Agarwal S, Foster WG (2010) Alcohol, drugs, caffeine, tobacco, and environmental contaminant exposure: reproductive health consequences and clinical implications. Crit Rev Toxicol 40(7): 633–652.

3. Lewis SE, Paro R, Borriello L, Simon L, Robinson L, et al. (2012) Long-term use of HU210 adversely affects spermatogenesis in rats by modulating the endocannabinoid system. Int J Androl doi: 10.1111/j.1365–2605.2012.01259.x.

4. Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima ST, et al. (2001) Sperm morphology, motility, and concentration in fertile and infertile men. New England Journal of Medicine 345(19): 1388–1393.

5. Lewis SE (2007) Is sperm evaluation useful in predicting human fertility?. Reproduction 134: 31–40.

6. Lefièvre L, Bedu-Addo K, Conner SJ, Machado-Oliveira GS, Chen Y, et al. (2007) Counting sperm does not add up any more: time for a new equation?. Reproduction 133(4): 675–684.

7. Barratt CL, Aitken RJ, Björndahl L, Carrell DT, de Boer P, et al. (2010) Sperm DNA: organization, protection and vulnerability: from basic science to clinical applications–a position report. Hum Reprod 25(4): 824–838.

8. Battista N, Pasquariello N, Di Tommaso M, Maccarrone M (2008) Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction. J Neuroendocrinol 20 (1): 82–89.

9. Lewis SE, Maccarrone M (2009) Endocannabinoids, sperm biology and human fertility. Pharmacol Res 60(2): 126–131.

10. Bari M, Battista N, Pirazzi V, Maccarrone M (2011) The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci 16: 498–516.

11. List A, Nazar B, Nyquist S, Harclerode J (1977) The effects of delta9-tetrahydrocannabinol and cannabidiol on the metabolism of gonadal steroids in the rat. Drug Metab Dispos 5(3): 268–272.

12. Wenger T, Ledent C, Csernus V, Gerendai I (2001) The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem Biophys Res Commun 284(2): 363–368.

13. Wang H, Dey SK, Maccarrone M (2006) Jekyll and Hyde: two faces of cannabinoid signaling in male and female fertility. Endocr Rev 27(5): 427–448.

14. Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6(3): 257–268.

15. Di Marzo V (2008) Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 160: 1–24.

16. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161–202.

17. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, et al. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563–583.

18. El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, et al. (2009) Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE 4: e4579.

19. Cacciola G, Chioccarelli T, Mackie K, Meccariello R, Ledent C, et al. (2008) Expression of type-1 cannabinoid receptor during rat postnatal testicular development. Possible Involvement in adult Leydig cell differentiation. Biol Reprod 79: 758–765.

20. Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S (2005) Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. Eur J Pharmacol 525: 150–153.

21. Matias I, Bisogno T, Di Marzo V (2006) Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes 30: S7–S12.

22. Howlett AC, Blume LC, Dalton GD (2010) CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem 17(14): 1382–1393.

23. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441): 61–65.

24. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329–332.

25. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, et al. (2009) Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 29: 4564–4570.

26. Maccarrone M (2008) CB2 receptors in reproduction. Br J Pharmacol 153(2): 189–198.

27. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699–2704.

28. Moriconi A, Cerbara I, Maccarrone M, Topai A (2010) GPR55: Current knowledge and future perspectives of a purported “Type-3” cannabinoid receptor. Curr Med Chem 17(14): 1411–1429.

29. Di Marzo V, De Petrocellis L (2010) Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 17(14): 1430–1449.

30. Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687–1707.

31. Muccioli GG (2010) Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 15: 474–483.

32. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279(7): 5298–5305.

33. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163(3): 463–468.

34. Yates ML, Barker EL (2009) Organized trafficking of anandamide and related lipids. Vitam Horm 81: 25–53.

35. Kaczocha M, Glaser ST, Deutsch DG (2009) Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A 106(15): 6375–6380.

36. Maccarrone M, Dainese E, Oddi S (2010) Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35(11): 601–608.

37. McKinney MK, Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74: 411–432.

38. Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121(1–2): 149–158.

39. Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, et al. (2002) N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids 121(1–2): 211–227.

40. Gye MC, Kang HH, Kang HJ (2005) Expression of cannabinoid receptor 1 in mouse testes. Arch Androl 51(3): 247–255.

41. Maccarrone M, Cecconi S, Rossi G, Battista N, Paeselli R, et al. (2003) Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells. Endocrinology 144: 20–28.

42. Rossi G, Gasperi V, Paro R, Barsacchi D, Cecconi S, et al. (2007) Follicle-stimulating hormone activates fatty acid amide hydrolase by protein kinase A and aromatase-dependent pathways in mouse primary Sertoli cells. Endocrinology 148: 1431–1439.

43. Schuel H, Chang MC, Berkery D, Schuel R, Zimmerman AM, et al. (1991) Cannabinoids inhibit fertilization in sea urchins by reducing the fertilizing capacity of sperm. Pharmacol Biochem Behav 40(3): 609–615.

44. Maccarrone M, Barboni B, Paradisi A, Bernabò N, Gasperi V, et al. (2005) Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction. J Cell Sci 118(Pt 19): 4393–4404.

45. Ricci G, Cacciola G, Altucci L, Meccariello R, Pierantoni R, et al. (2007) Endocannabinoid control of sperm motility: the role of epididymus. Gen Comp Endocrinol 153: 320–322.

46. Cacciola G, Chioccarelli T, Ricci G, Meccariello R, Fasano S, et al. (2008) The endocannabinoid system in vertebrate male reproduction: a comparative overview. Mol Cell Endocrinol 286: S24–30.

47. Rossato M (2008) Endocannabinoids, sperm functions and energy metabolism. Mol Cell Endocrinol 286(1–2 Suppl 1): S31–S35.

48. Francavilla F, Battista N, Barbonetti A, Vassallo MR, Rapino C, et al. (2009) Characterization of the endocannabinoid system in human sperm and involvement of TRPV1 vanilloid receptor in their fertilizing ability. Endocrinology 150(10): 4692–4700.

49. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, et al. (2009) The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106(27): 11131–11136.

50. Catanzaro G, Battista N, Rossi G, Di Tommaso M, Pucci M, et al. (2011) Effect of capacitation on the endocannabinoid system of mouse sperm. Mol Cell Endocrinol 343(1–2): 88–92.

51. Fasano S, Meccariello R, Cobellis G, Chianese R, Cacciola G, et al. (2009) The endocannabinoid system: an ancient signaling involved in the control of male fertility. Ann N Y Acad Sci 1163: 112–124.

52. Pierantoni R, Cobellis G, Meccariello R, Cacciola G, Chianese R, et al. (2009) CB1 activity in male reproduction: mammalian and nonmammalian animal models. Vitam Horm 81: 367–387.

53. Battista N, Meccariello R, Cobellis G, Fasano S, Di Tommaso M, et al. (2012) The role of endocannabinoids in gonadal function and fertility along the evolutionary axis. Mol Cell Endocrinol 355(1): 1–14.

54. Chang MC, Berkery D, Schuel R, Laychock SG, Zimmerman AM, et al. (1993) Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 36(4): 507–516.

55. Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S (1994) Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci U S A 91(16): 7678–7682.

56. Schuel H, Burkman LJ, Lippes J, Crickard K, Mahony MC, et al. (2002) Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev 63(3): 376–387.

57. Schuel H, Burkman LJ (2005) A tale of two cells: endocannabinoid-signaling regulates functions of neurons and sperm. Biol Reprod 73(6): 1078–1086.

58. Rossato M, Ion Popa F, Ferigo M, Clari G, Foresta C (2005) Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J Clin Endocrinol Metab 90(2): 984–991.

59. Fezza F, Gasperi V, Mazzei C, Maccarrone M (2005) Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D activity. Anal Biochem 339(1): 113–120.

60. World Health Organization (2010) WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 5th edition Geneva: WHO Press.

61. World Health Organization (1999) WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 4th edition Cambridge: Cambridge University Press.

62. Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, et al. (1987) New method of evaluating sperm morphology with predictive value for human in vitro fertilization. Urology 30: 248–251.

63. Pasquariello N, Catanzaro G, Marzano V, Amadio D, Barcaroli D, et al. (2009) Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem 284(43): 29413–29426.

64. Bari M, Tedesco M, Battista N, Pasquariello N, Pucci M, et al. (2011) Characterization of the endocannabinoid system in mouse embryonic stem cells. Stem Cells Dev 20(1): 139–147.

65. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, et al. (2007) Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64(2): 219–229.

66. Pertwee RG (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17(14): 1360–1381.

67. Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, Piomelli D (2000) Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol 408: 161–168.

68. Glanemann C, Loos A, Gorret N, Willis LB, O’Brien XM, et al. (2003) Disparity between changes in mRNA abundance and enzyme activity in Corynebacterium glutamicum: implications for DNA microarray analysis. Appl Microbiol Biotechnol 61(1): 61–8.

69. Colombo G, Rusconi F, Rubino T, Cattaneo A, Martegani E, et al. (2009) Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9-tetrahydrocannabinol. J Mol Neurosci. 37(2): 111–22.

70. Cobellis G, Cacciola G, Scarpa D, Meccariello R, Chianese R, et al. (2006) Endocannabinoid system in frog and rodent testis: type-1 cannabinoid receptor and fatty acid amide hydrolase activity in male germ cells. Biol Reprod 75(1): 82–89.

71. Gervasi MG, Rapanelli M, Ribeiro ML, Farina M, Billi S, et al. (2009) The endocannabinoid system in bull sperm and bovine oviductal epithelium: role of anandamide in sperm-oviduct interaction. Reproduction 137(3): 403–414.

72. Maccarrone M, Falciglia K, Di Rienzo M, Finazzi-Agrò A (2002) Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids 66(2–3): 309–317.

73. Habayeb OM, Taylor AH, Finney M, Evans MD, Konje JC (2008) Plasma anandamide concentration and pregnancy outcome in women with threatened miscarriage. JAMA 299(10): 1135–1136.

74. Gervasi MG, Osycka-Salut C, Caballero J, Vazquez-Levin M, Pereyra E, et al. (2011) Anandamide capacitates bull spermatozoa through CB1 and TRPV1 activation. PLoS One 6(2): e16993.

75. Shukla KK, Mahdi AA, Rajender S (2012) Ion Channels in Sperm Physiology, Male Fertility and Infertility. J Androl doi: 10.2164/jandrol.111.015552.

76. Yanagimachi R (1988) Mammalian Fertilization. In: Knobil E Neill JD Ewing LL, Market CL editors. The Physiology of Reproduction Vol 1. New York, NY: Raven Press.

77. Lindemann CB, Kanous KS (1989) Regulation of mammalian sperm motility. Arch Androl 23(1): 1–22.

78. Buffone MG, Ijiri TW, Cao W, Merdiushev T, Aghajanian HK, et al. (2012) Heads or tails? Structural events and molecular mechanisms that promote mammalian sperm acrosomal exocytosis and motility. Mol Reprod Dev 79(1): 4–18.

79. Whan LB, West MC, McClure N, Lewis SE (2006) Effects of delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro. Fertil Steril 85(3): 653–660.

80. Cobellis G, Ricci G, Cacciola G, Orlando P, Petrosino S, et al. (2010) A gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up. Biol Reprod 82(2): 451–458.

81. Giwercman A, Lindstedt L, Larsson M, Bungum M, Spano M, et al. (2010) Sperm chromatin structure assay as an independent predictor of fertility in vivo: a case-control study. Int J Androl 33(1): e221–e227.